Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483–9.

Article  CAS  PubMed  Google Scholar 

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72:3457–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy. Clin Cancer Res. 2018;24:927–38.

Article  CAS  PubMed  Google Scholar 

Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, et al. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocr Relat Cancer. 2016;23:35–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:e27861.

Article  PubMed  PubMed Central  Google Scholar 

Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, et al. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. Oncogene. 2021;40:3087–100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell. 2020;37:584–98.e11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa tumor microenvironment. Cancer Microenviron. 2011;4:283–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, et al. Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. Oncogene. 2019;38:5339–55.

Article  CAS  PubMed  Google Scholar 

Li D, Xu W, Chang Y, Xiao Y, He Y, Ren S. Advances in landscape and related therapeutic targets of the prostate tumor microenvironment. Acta Biochim Biophys Sin. 2023;55:956–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

Article  CAS  PubMed  Google Scholar 

Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer. 2014;50:1090–9.

Article  CAS  PubMed  Google Scholar 

Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, et al. A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2015;21:3862–9.

Article  CAS  PubMed  Google Scholar 

Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer. 2022;21:132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joseph DB, Henry GH, Malewska A, Iqbal NS, Ruetten HM, Turco AE, et al. Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. Prostate. 2020;80:872–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2015;136:E27–38.

Article  CAS  PubMed  Google Scholar 

Pak S, Suh J, Park SY, Kim Y, Cho YM, Ahn H. Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer. Front Oncol. 2022;12:972572.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, et al. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res. 1996;2:889–95.

CAS  PubMed  Google Scholar 

Hidalgo AA, Montecinos VP, Paredes R, Godoy AS, McNerney EM, Tovar H, et al. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. Biochem Biophys Res Commun. 2011;412:13–9.

Article  CAS  PubMed  Google Scholar 

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song M, He J, Pan QZ, Yang J, Zhao J, Zhang YJ, et al. Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression. Hepatology. 2021;73:1717–35.

Article  CAS  PubMed  Google Scholar 

Li J, Tang Z, Wang H, Wu W, Zhou F, Ke H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p. Biomed Pharmacother. 2018;97:1182–8.

Article  CAS  PubMed  Google Scholar 

Karagiannis GS, Saraon P, Jarvi KA, Diamandis EP. Proteomic signatures of angiogenesis in androgen-independent prostate cancer. Prostate. 2014;74:260–72.

Article  CAS  PubMed  Google Scholar 

Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Clark KC, Niranjan B, Chueh AC, Horvath LG, Taylor RA, et al. Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts. Mol Oncol. 2023;17:469–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128:2038–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milovanovic J, Todorovic-Rakovic N, Radulovic M. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. Cytokine. 2019;118:93–8.

Article  CAS  PubMed  Google Scholar 

Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol. 2012;12:18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

An H, Zhu Y, Xie H, Liu Y, Liu W, Fu Q, et al. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Tumour Biol. 2016;37:4523–9.

Article  CAS  PubMed  Google Scholar 

MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, et al. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res. 2007;5:737–48.

Article  CAS  PubMed  Google Scholar 

Maynard JP, Ertunc O, Kulac I, Baena-Del Valle JA, De Marzo AM, Sfanos KS. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol Cancer Res. 2020;18:153–65.

Article  CAS  PubMed  Google Scholar 

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, et al. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. Mol Oncol. 2018;12:1308–23.

Article  CAS  PubMed  PubMed Central